A 12-Week, phase 2a, randomized, subject and investigator blind, placebo-controlled trial to evaluate the effect of CP-741,952 [CP 741952] on weight loss in otherwise healthy overweight and obese adult subjects
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2007
At a glance
- Drugs CP 741952 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 22 Jun 2007 Status change from in progress to completed.
- 10 Oct 2006 New trial record.